A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

Stage 1: Inclusion criteria: * Male or female subjects between 45 and 78 years of age inclusive. * Willing and able to give informed consent. * Idiopathic PD, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria * Rest tremor amplitude score of ≥2 in any limb on question 3.17 of the MDS-UPDRS (ON state). * Anti-parkinsonian medication is fixed for at least 1 month prior to study entry * If MoCA\<22 subject must have a legally authorized representative (LAR) sign the consent, and must have a designated caregiver that agrees to ensure study protocols followed. This includes accompanying patient to study visits and being available for study phone calls. * Must have a driver to drive them to and from study visits * Has a significant other (someone who knows the subject well) that is appropriate for doing the NPI assessment, can accompany patient to study visits, and agrees to do so * Agrees to not take more than 1 gram per day of acetaminophen, due to a possible interaction with study drug that could increase risk of hepatotoxicity. Exclusion criteria: * Known or suspected allergy to cannabinoids or excipients used in the study drug formulation. * Cannabinoids taken currently or in the previous 30 days. * History of drug or alcohol dependence; defined by prior inpatient stay(s) for this or that patient stats s/he has a history of this. * Use of dopamine blockers within 180 days and amphetamine, cocaine, and MAO-A inhibitors within 90 days of base…